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Abstract
Purpose
To study the potential of (99m)Tc-Mebrofenin hepatobiliary scintigraphy (HBS) in identifying
the short-term variations of liver function after stereotactic body radiotherapy (SBRT) for
liver cancers.
Material and methods
We treated with SBRT 3 patients (pts) affected by a cholangiocarcinoma and 3 patient pre-
senting liver metastases (3x15 Gy, 4 pts; 5x8 Gy, 1 pt; 6x5 Gy, 1 pt). All patients received
HBS before and 3 months after SBRT, which were co-registered with the simulation CT-
scan. Structures corresponding to isodoses from 10–90 Gy were created, with intervals of
10 Gy. Finally, the variations of the mean activity (MBq) in each isodose structure have
been calculated. Then, a linear regression analysis was performed.
Results
We showed a linear reduction of the activity, significantly related to the delivered dose
(p<0.01), and a reduction of the perfusion of 0.78% for each delivered Gy. The linear equa-
tion has predictive value of the loss of the function of 96% (R2 = 0.9605).
Conclusions
HBS could improve treatment plans for liver SBRT, by allowing the identification of the liver
function variations after SBRT and, potentially, the prediction of remnant liver function after
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SBRT. These preliminary results should be confirmed on long-term prospective data and
larger population.
Introduction
Stereotactic body radiotherapy (SBRT) is one of the therapeutic options in the treatment of
primary or secondary liver cancers not suitable for surgery [1,2], with encouraging rates of
local control (LC) and overall survival (OS) [3,4].
Radiation-induced liver disease (RILD) is a rare, but severe potential side effect of liver irra-
diation: several dosimetric constraints have been established and are available in the literature
to reduce the risk of RILD [5,6]. Noteworthy, these constraints are based on the doses deliv-
ered on the whole liver, delineated as it appears on the simulation CT scan, but they do not
take into account the regional variations of the liver function, potentially related to concomi-
tant liver diseases (i.e., cirrhosis in patients treated for a hepatocellular cancer [HCC], hepatic
toxicity of previous systemic treatments, the effects of previous local ablative therapies, etc).
99mTc-mebrofenin hepatobiliary scintigraphy (HBS) is a non-invasive nuclear medicine
technique, which provides visual and quantitative information on both total and regional liver
function. HBS is used on a regular basis in the preoperative assessment of future remnant liver
function, follow-up after preoperative portal vein embolization, and evaluation of postopera-
tive liver regeneration [7]. However, the integration of HBS in the optimization of radiother-
apy treatment plans has been only rarely reported [8,9]. Only one case report has been
published exploring the potential of HBS in monitoring the short-term variations of hepatic
function (HF) after liver SBRT [10].
To the best of our knowledge, we report the first clinical experience exploring the role of
HBS in the evaluation of the short-term radiation induced variations of HF after SBRT.
Materials and methods
HBS imaging procedure
Liver function was estimated from hepatic scintigraphy starting with a dynamic acquisition of
36 frames of 10 seconds (128 × 128-pixel matrix) starting immediately after administration of
200 MBq of 99mTc-mebrofenin (Bridatec1, GE Healthcare, Chalfont St. Giles, United King-
dom). Then, a fast SPECT/CT (Intevo1, Siemens, Erlangen, Germany) with 60 projections of
8 seconds was performed with a low-dose attenuation correction CT using iterative recon-
struction (25 iterations × 4 subsets, 3D Gaussian FWHM 10 mm). Normalized hepatic clear-
ance (in%/min/m2) was computed according the method of Ekman [11], with good
reproducibility.
Population
Between 08.2014 and 09.2015, 6 patients presented a primary (n = 3) or a metastatic liver can-
cer (n = 3) with an indication of SBRT. Clinical characteristics of the patients are summarized
in Table 1. The total number of treated lesions was 6. For each patient, there was a clinical indi-
cation to performing a HBS, because of a clinical history of chronic liver diseases (i.e., cirrho-
sis, n = 3) or because of chemotherapy related toxicity before SBRT (n = 3). Table 1
summarizes data of these patients.
HBS for SBRT toxicity evaluation
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Imaging procedures
All patients underwent a HBS before the beginning of the treatment with a mean interval of 47
days (range: 13–136). The images of the HBS were co-registered with the planning phase of the
CT scan. The HBS was performed in the 13–48 days before the beginning of SBRT, except for
one patient. This patient initially received a HBS in the 20 days preceding the treatment.
Unfortunately, he presented a severe bowel occlusion before the beginning of SBRT, treated
surgically and needing some weeks of hospitalization. When he came back to our attention to
receive SBRT on the liver metastases, we considered that the HBS the he had already under-
gone could still be considered adequate, as he did not receive new treatments potentially
changing his hepatic function.
All patients underwent a 4D, contrast enhanced simulation CT scan. In patients treated
with Cyberknife (Accuray, Switzerland), 3–4 fiducials were implanted before simulation CT-
scan to allow the tracking of the lesion during the treatment. The gross tumor volume (GTV)
was contoured with Velocity software (Varian, USA) after deformable or rigid image registra-
tion with MRI in all the patients. In patients treated with Cyberknife and an online fiducial-
based tracking, a 5-mm margin was added to the GTV to obtain the planning target volume
(PTV). In patients treated with CyberKnife but without tracking, or with Tomotherapy or
VMAT, an internal target volume (ITV) was defined on the 10 phases of the 4D-CT scan and a
5-mm margin was added to the ITV to obtain the PTV. The organs at risk usually contoured
Table 1. Principal clinical and therapeutic features of the 6 patients enrolled in this analysis.
Patient
n.
Treatment
indication
Age at the
time of
the SBRT
PTV
volume
(cc)
Total dose/
dose
fraction
(Gy)
Variation of the
activity after SBRT
in the irradiated
liver
Other treatments in the interval
between SBRT and HBS
Liver function
enzymes before
SBRT
Liver function
enzymes post SBRT
at the moment of
HBS
1 Liver
Metastases
(lung cancer)
66 85 45/15 -17% Chemotherapy with gemcitabine until
15 days before the SBRT
Immunotherapy with Nivolumab
started 15 days after the SBRT (ongoing
at the moment of post treatment HBS)
AST = 25
ALT = 37
GGT = 60
ALP = 93
AST = 27
ALT = 35
GGT = 69
ALP = 100
2 Liver
Metastases
(retal cancer)
56 236 30/5 -1% Chemotherapy with Folfiri + Cetuximab
stopped 48 days before the SBRT and
chemotherapy with Folfox + Avastin
started 19 days after the SBRT
AST = 24
ALT = 33
GGT = 230
ALP = 246
AST = 23
ALT = 36
GGT = 233
ALP = 259
3 Liver
Metastases
(sigmoid
cancer)
50 9 45/15 0% Radiofrequency of 3 other hepatic
metastases 15 days before HBS post-
SBRT. No other treatments in between
the 2 HBS.
AST = 230
ALT = 580
GGT = 404
ALP = 143
AST = 54
ALT = 108
GGT = 487
ALP = 208
4 HCC 84 147 45/15 -11% Not AST = 39
ALT = 60
GGT = 209
ALP = 203
AST = 32
ALT = 31
GGT = 184
ALP = 164
5 HCC 78 182 40/8 -1% Not AST = 19
ALT = 9
GGT = 466
ALP = 193
AST = 21
ALT = 12
GGT = 460
ALP = 199
6 HCC 82 122 40/8 0% Not AST = 27
ALT = 23
GGT = 46
ALP = 48
AST = 22
ALT = 19
GGT = 30
ALP = 44
Legend: HCC = Hepato-Cellular Carcinoma; PTV = Planning Target Volume; SBRT = Stereotactic Body Radiotherapy; HBS = Hepato-Biliary Scintigraphy;
AST = Aspartate Aminotransferase; ALT = Alanine Transaminase; ALP = Alkaline Phosphatase; GGT = Gamma-glutamyl Transferase.
We consider as irradiated liver, the liver receiving at least 5 Gy.
https://doi.org/10.1371/journal.pone.0204013.t001
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for a liver SBRT were delineated. Moreover, we also identified the 700 cc of the liver outside
the PTV showing the higher activity at HBS, and we call this structure “healthy liver” (HL).
Then, a treatment plan was computed. Patients were treated with Cyberknife (n = 3), helical
Tomotherapy (n = 2; Accuray, CH), or with volumetric modulated arc therapy (VMAT, n = 1;
Elekta, UK). The usual constraints adopted in our Department for treatment plan optimization
were used [12]. A further constraint was used on the HL: we established that the mean dose on
this structure should be< 15 Gy. Noteworthy, it was a “secondary constraint”, as in no cases
we allowed to violate the correct PTV coverage and/or the respect of the internationally
accepted constraints only to allow the respect of the constraint on the HL.
After a mean time of 95 days (range: 89–112), patients underwent a second HBS. Also these
images were co-registered with the planning phase of the simulation CT-scan. The 2 Gy-per-
fraction equivalent dose (EQD2) was calculated (alpha/beta ratio = 10 Gy for acute toxicity).
On the planning phase of the simulation CT-scan, we identified the isodoses, from 10–90 Gy,
with an interval of 10 Gy between each isodose (10 Gy, 20 Gy, 30 Gy, etc). Structures corre-
sponding to the lower dose cropped with the following higher one were created. For example,
considering the 10 Gy structure, we cropped the parts of the structure corresponding to 20 Gy
(or more), which were inside the 10 Gy. Then, we cropped the parts of the structure corre-
sponding to 30 Gy (or more) structure, which were inside the 20 Gy. We made the same for all
the isodoses, thus obtaining several “X Gy crop” structures, which represented the interval of
doses between two following considered isodoses (between 10 and 20 Gy, between 20 and 30
Gy, etc . . .). Fig 1 shows an example of 10 Gy isodose (in white) and 20 Gy isodose (in red) on
the same CT scan image. In green, the resulting cropped structure (10–20 Gy crop). To take
into account the impact of some external variables on the final liver activity (weight of the
patient, injected activity, time of the image acquisition, etc), for each HBS we performed an
internal normalization between the mean activity of the irradiated liver (i.e., the liver receiving
at least 5 Gy) and the mean activity of the not-irradiated liver (i.e. the liver receiving less than 5
Gy). We calculated the mean normalized activity (MBq) in the each “X Gy crop” before and
after the treatment (see Fig 1). Then, we calculated the difference (in%) between the pre- and
post-treatment values of mean activity (deltaAct). It gave the information about the loss of HF
related to the considered interval of dose.
Then a linear regression analysis (LRA) has been performed to establish if there was a pre-
dictable relation between the delivered dose and the deltaAct in each “X Gy crop”.
All patients were informed about the goal of the HBS and our analysis, and they gave their
verbal consent, and it was recorded in the clinical chart of each patient. The Ethics Committee
of the Swiss Vaud Canton also approved this study and the methods adopted obtain the
patients consent.
Results
All patient data were available for the analysis. Fig 2 shows the results of the LRA. A significant
linear relation was found between the delivered dose and the loss of HF: the higher the deliv-
ered dose, the higher the loss of HF (p = 0.0009). Our analysis shows that there is mean loss of
0.78% of the HF for each delivered Gray. The predictive value of the LRA was 96%, meaning
that when we adopt the obtained equation, and we replace the x with a given dose, we have
96% of possibility of predicting correctly the loss of HF at 3 months.
Discussion
In this feasibility study we aimed at the evaluation of HBS as imaging tool in the prediction of
loss of HF. Our study shows that the integration of HBS is feasible and that it could be a useful
HBS for SBRT toxicity evaluation
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tool to identify the impact of radiotherapy on the HF. Indeed, with our approach, we showed
the linar correlation between the delivered dose and the 3-month loss of HF.
Although HBS is regularly used in the pre-surgical assessment of the remnant liver function
[7], its use has been only rarely reported in the radiation oncology literature. Indeed, only 2
studies have been published exploring its role in the treatment plan optimization for liver tar-
gets [8,9]. In the study by Shen et al., the authors only illustrated a procedure for the inclusion
of 99mTc-mebrofenin HBS for optimizing radiotherapy for primary and secondary cancers,
but no clinical data are described [9].
The study by Gunve´n et al. reported the potential interest of mebrofenin HBS in identifying
the late side effects of liver irradiation on a population of 11 long-survivor patients affected by
primary or secondary liver tumors [8]. Eight of 11 patients received a HBS after the treatment,
at the earlier, 3 years after SBRT. The authors concluded that results of HBS did not relate to
the irradiation. In their opinion, this lack of relationship suggests that changes due to the
SBRT were too subtle and/or too short-lived to be detected. However, in their study no pre-
Fig 1. A typical image in our study: In red the 20 Gy isodoses (EQD2), in white the 10 Gy (EQD2) for a patient treated with VMAT. In green, the cropped structure
(10–20 Gy crop). In this cropped structure we calculated the difference in the mean activity before and after radiotherapy. The same kind of structures and analyses were
performed for all the so-obtained crop structures, calculated and defined with an interval of 10 Gy (EQD2). In violet we showed the PTV.
https://doi.org/10.1371/journal.pone.0204013.g001
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SBRT HBS was available, so it was not possible to assess, in the post-treatment setting, any rela-
tionship between the dose and the variation of hepatic function. Moreover, most of their
patients received several systemic or surgical treatments after SBRT and before HBS, a factor
that could surely impact their results.
An obvious and major limitation of our study is that it only includes a mixed population of
6 liver cancer patients. The creation of a model of activity reduction on this small number of
patients of varied diagnosis is not likely to be used clinically, validated or reproduced. The
results of the linear regression analysis are presented only to complete the results presented in
the Table 1. Indeed, although SBRT was not responsible for major loss of function in the irra-
diated liver, it can be found, with our approach, that in the areas of higher delivered doses the
loss of function was higher, up to more than 40%, as showed in the graph of the linear
regression.
In our study, we only aimed at exploring, in this very preliminary phase, the feasibility of
the integration of HBS in treatment plan optimization. Clinical data that are presented could
not be a final model, but only a way to show the potential of our approach, that must be con-
firmed in large, prospective cohorts. Moreover, some of the treatments delivered after SBRT
and before the second HBS in some of the patients (see Table 1) could potentially affect the
results. Nevertheless, the analysis of the hepatic blood chemistry did not show a deterioration
of the liver function, meaning that these treatments did not negatively affect the results of our
analysis. It should be noted that the first evaluation of the hepatic blood test has been per-
formed 3 months after the end of RT. So, we could not know if we missed any transient varia-
tion of these parameters happening in these 3 months. In any case, none of our patients
showed major variations at 3 months. Whether this result is related or not to our healthy liver-
sparing approach is difficult to be established. Considering the small number of patients, we
did not perform ad hoc histology based analyses (i.e., primary vs secondary liver cancers), but
we acknowledge that it would be of clear interest, also to show different subclinical variations,
which could depend on the baseline conditions of the liver. Indeed, it could be argued, for
example, that a cirrhotic liver could present a different tolerance to radiation than a normal
liver. We planned these kinds of analyses in a prospective trial with larger and more homoge-
neous populations. It should also noticed that the goal of the study was not to establish the
effectiveness of SBRT in liver cancer (that could be potentially affected by the histology of the
treated lesions), but to assess the potential clinical usefulness of this innovative approach.
Fig 2. Results of the linear regression analysis.
https://doi.org/10.1371/journal.pone.0204013.g002
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Nevertheless, our results are hypothesis-generating, as they support the adoption of nuclear
medicine and molecular imaging not only for target delineation, but also to introduce new
functionally based approaches in treatment plan optimization aiming at the reduction of the
treatment-related toxicities. These approaches are appealing in the modern era of intensity-
modulated radiotherapy, as it allows the selective sparing of certain areas of interest. For exam-
ple, looking at the available data, SBRT could be responsible for an early decline in the Child-
Pugh score in almost 15–30% of the patients treated with SBRT for a HCC [13–16]. The inte-
gration of functional imaging allows the identification of the more functioning areas of the
liver, thus allowing the possibility of selectively spare these areas. Such a kind of approach has
been already successfully adopted for the treatment of thoracic targets [17]. Moreover, these
function-based approaches could allow, in the future, the analysis of the effect of the same dose
on different baseline level of HF. The assumption of this kind of analyses is that areas of the
liver contributing lesser to the whole HF could be characterized by different radiosensitivity
compared to more functioning ones, and then that the same dose could affect them differently.
Then, it opens to new interesting horizons, as it could improve the optimization of the radio-
therapy plans, which could be then tailored on the distribution of the individual liver function.
Such kind of studies would allow the identification of predictive algorithms to calculate the
remnant HF after liver SBRT, thus tailoring the treatments and the indications, and opening
the possibility of treat with SBRT also patients with more limiting HF, by selecting sparing
more functional areas and by defining functional based constraints, ensuring a remnant HF
still compatible with life.
Noteworthy, by repeating HBS at different moments during and after SBRT, our approach
allows to obtain interesting insight about the timescale of liver repair and regeneration, and
then it could be an exciting tool to understand the radiobiology of liver, and deserves further,
prospective evaluations.
Conclusions
Our pilot study shows the interests of integrating hepatobiliary scintigraphy in the treatment
plans of liver SBRT. This organ function-adapted approach allows the evaluation of the func-
tion impact of SBRT. We found a linear correlation between the delivered dose and the loss of
hepatic function. Larger populations and long-term evaluations are warranted to confirm our
data and the usefulness of optimization approaches based on the organs at risk function.
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